Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06793215 | RECRUITING | Non-Small Cell Lung Cancer

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sponsor:

Hoffmann-La Roche

Brief Summary:

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).

Condition or disease

Non-Small Cell Lung Cancer

KRAS G12C Lung Cancer

Intervention/treatment

Divarasib

Pembrolizumab

Pemetrexed

Carboplatin

Cisplatin

Phase

PHASE3

Study Type : INTERVENTIONAL
Estimated Enrollment : 600 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Actual Study Start Date : 2025-12-01
Estimated Primary Completion Date : 2028-11-30
Estimated Study Completion Date : 2030-10-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • * Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
  • * Measurable disease, as defined by RECIST v1.1
  • * No prior systemic treatment for advanced or metastatic NSCLC
  • * Documentation of the presence of a KRAS G12C mutation
  • * Documentation of known PD-L1 expression status in tumor tissue
  • * Availability of a representative tumor specimen
  • * Adequate end-organ function
  • * Eligible to receive a platinum-based chemotherapy regimen
Exclusion Criteria Related to NSCLC
  • * Known concomitant second oncogenic driver with available targeted treatment
  • * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • * Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \>=2 weeks prior to randomization
  • * History of leptomeningeal disease
  • * Uncontrolled tumor-related pain
  • * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently)
Exclusion Criteria Related to Current or Prior Treatments
  • * Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study
  • * Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung \>30Gy within 6 months prior to randomization
  • * Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
  • * Treatment with systemic immunosuppressive or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors
  • * Current treatment with medications that are well known to prolong the QT interval
  • * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to randomization
  • * Prior allogeneic stem cell or solid organ transplantation
Exclusion Criteria Related to General Health
  • * History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival \[OS\] rate \>90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer
  • * Individuals with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis), malabsorption syndrome, conditions that would interfere with enteral absorption
  • * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest computed tomography scan
  • * Significant cardiovascular disease within 3 months prior to screening
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Location Details

NCT06793215

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Alaska

Alaska Oncology and Hematology

Anchorage, alaska, United States, 99508

RECRUITING

United States, Florida

BioResearch Partner

Hialeah, florida, United States, 33013

RECRUITING

United States, Georgia

Summit Cancer Care PC

Savannah, Georgia, United States, 31405

RECRUITING

United States, Illinois

Hope and Healing Cancer Services

Hinsdale, Illinois, United States, 60521

RECRUITING

United States, road cancer

Profound Research, LLC

Farmington Hills, road cancer, United States, 48334

RECRUITING

United States, Texas

University of Texas Health Center at Tyler

Tyler, Texas, United States, 75708

RECRUITING

Hong Kong,

Queen Mary Hospital

Hong Kong, Hong Kong,

RECRUITING

Taiwan,

Medical University Chunng-Hospital

City fast, Taiwan, 80756

RECRUITING

Taiwan,

Chung Shan Medical University Hospital

Taichung, Taiwan, 40201

RECRUITING

Taiwan,

Taipei Veterans General Hospital

Taipei, Taiwan, 112